
Contents

1. Immune Reactions Towards Biopharmaceuticals – a General, Mechanistic Overview	1
<i>Camilla Foged and Anne Sundblad</i>	
2. Clinical Aspects of Immunogenicity to Biopharmaceuticals	27
<i>Simona Malucchi and Antonio Bertolotto</i>	
3. Assessment of Unwanted Immunogenicity	57
<i>Meenu Wadhwa and Robin Thorpe</i>	
4. Models for Prediction of Immunogenicity	75
<i>Erwin L. Roggen</i>	
5. Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and Biosimilars	97
<i>Marco van de Weert and Eva Horn Møller</i>	
6. Case Study: Immunogenicity of rhEPO	113
<i>Arno Kromminga and Gilbert Deray</i>	
7. Case Study: Immunogenicity of Interferon-Beta	127
<i>Klaus Bendtzen and Arno Kromminga</i>	
8. Case Study: Immunogenicity of Insulin	137
<i>Henriette Mersebach, Fannie Smith, Thomas Sparre and Lisbeth Bjerring Jensen</i>	
9. Case Study: Immunogenicity of Factor VIII	147
<i>Silke Ehrenforth and Stephanie Seremetis</i>	
10. Case Study: Immunogenicity of Natalizumab	173
<i>Meena Subramanyam</i>	
11. Case Study: Immunogenicity of Anti-TNF Antibodies	189
<i>Klaus Bendtzen</i>	
12. Heparin-Induced Thrombocytopenia	205
<i>Carmel A. Celestin and John R. Bartholomew</i>	
13. Presenting an Immunogenicity Risk Assessment to Regulatory Agencies	239
<i>Paul Chamberlain</i>	
Subject Index	259